KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 81 filers reported holding KEROS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,641,262 | -5.0% | 176,953 | +19.7% | 0.00% | 0.0% |
| Q2 2023 | $5,938,001 | +4.7% | 147,785 | +11.3% | 0.00% | 0.0% |
| Q1 2023 | $5,669,194 | -11.5% | 132,768 | -0.4% | 0.00% | 0.0% |
| Q4 2022 | $6,403,563 | +39.4% | 133,352 | +9.2% | 0.00% | 0.0% |
| Q3 2022 | $4,595,000 | +62.7% | 122,116 | +19.5% | 0.00% | +100.0% |
| Q2 2022 | $2,824,000 | -48.5% | 102,175 | +1.4% | 0.00% | -50.0% |
| Q1 2022 | $5,479,000 | -4.8% | 100,740 | +2.4% | 0.00% | 0.0% |
| Q4 2021 | $5,754,000 | +47.6% | 98,336 | -0.2% | 0.00% | +100.0% |
| Q3 2021 | $3,899,000 | +16.8% | 98,544 | +25.4% | 0.00% | 0.0% |
| Q2 2021 | $3,338,000 | -7.0% | 78,584 | +34.8% | 0.00% | 0.0% |
| Q1 2021 | $3,589,000 | -8.7% | 58,310 | +4.6% | 0.00% | -50.0% |
| Q4 2020 | $3,932,000 | +132.4% | 55,733 | +27.1% | 0.00% | +100.0% |
| Q3 2020 | $1,692,000 | +3.9% | 43,849 | +1.0% | 0.00% | 0.0% |
| Q2 2020 | $1,629,000 | – | 43,407 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |